STOCK TITAN

M28/Marc Elia Report 5.9% Position in Curis Including 99,108 Warrants

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

M28 Capital Management LP and Marc Elia report beneficial ownership of 620,167 shares of Curis common stock, representing 5.9% of the outstanding class when assuming exercise of reported warrants. The reported stake includes 99,108 shares issuable upon exercise of warrants, and the percentage is calculated using an aggregate share base of 10,561,358 shares.

The filing shows the reporting persons possess only shared voting and dispositive power over these shares, and it certifies the holdings were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control.

Positive

  • Disclosure of a >5% stake (5.9%) by M28 Capital and Marc Elia, increasing transparency for investors
  • Position includes 99,108 shares issuable upon exercise of warrants, clarifying potential future ownership
  • Filing certifies holdings were acquired in the ordinary course and not to influence control, indicating passive intent

Negative

  • None.

Insights

TL;DR A passive investor disclosed a material 5.9% position, including warrants; no sole control claimed.

The Schedule 13G/A indicates M28 Capital and Marc Elia collectively hold 620,167 shares, equal to 5.9% of Curis on a fully assumed basis including 99,108 warrant-derived shares. Ownership is reported as shared voting and dispositive power only, consistent with a passive investment under Rule 13d-1(b). The filing’s certification that the stake was acquired in the ordinary course and not to influence control reduces the likelihood of near-term activist engagement.

TL;DR A significant minority holding disclosed with shared control; governance impact appears limited.

From a governance perspective, a 5.9% position is sizable but below a controlling threshold. The absence of sole voting or dispositive power and the explicit certification that the position is not intended to change control suggest limited immediate influence on board or strategic decisions. The inclusion of warrants (99,108 shares) is material to potential dilution and should be monitored, but the filing conveys passive intent.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Includes 99,108 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 99,108 shares of Common Stock issuable upon exercise of warrants.


SCHEDULE 13G



M28 Capital Management LP
Signature:/s/ Christopher M. Taliercio
Name/Title:Christopher M. Taliercio, President & Chief Compliance Officer, By: M28 Capital Management GP LLC
Date:08/13/2025
Marc Elia
Signature:/s/ Marc Elia
Name/Title:Marc Elia, Individually
Date:08/13/2025

FAQ

What stake does M28 Capital and Marc Elia report in Curis (CRIS)?

They report beneficial ownership of 620,167 shares, representing 5.9% of the class on a fully assumed basis.

Does the reported stake in CRIS include warrants or other convertible instruments?

Yes. The filing states the position includes 99,108 shares issuable upon exercise of warrants.

What share count is the 5.9% percentage based on for CRIS?

The percentage is calculated using an aggregate of 10,561,358 shares outstanding as reported by the company.

Who filed the Schedule 13G/A for CRIS?

The filing was made by M28 Capital Management LP and Marc Elia (the Chief Investment Officer and related reporting person).

Do the reporting persons have sole voting or dispositive power over the CRIS shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power; all reported power is shared.

Does the filing state an intent to influence control of Curis (CRIS)?

No. The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control.
Curis

NASDAQ:CRIS

CRIS Rankings

CRIS Latest News

CRIS Latest SEC Filings

CRIS Stock Data

15.13M
12.02M
7.23%
34.32%
1.23%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
LEXINGTON